Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.70 |
| ▸ | MYC | P01106 | 1/20 | 0.53 |
| ▸ | MAX | P61244 | 1/20 | 0.53 |
| ▸ | CASP6 | P55212 | 1/20 | 0.51 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.51 |
| ▸ | ERN1 | O75460 | 1/20 | 0.48 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.47 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL27502524 | 0.85 | ALDH1A1 (0.88) | ALDH1A1TDP1ADAMTS4TSHRLMNA | |
| SCHEMBL2403547 | 0.85 | GPR35 (0.55) | ALDH1A1TDP1MYCMAXCASP6 | |
| SCHEMBL9310402 | 0.85 | ALDH1A1 (0.62) | ALDH1A1TDP1ADAMTS4POLBMAPK1 | |
| SCHEMBL28534102 | 0.85 | ALDH1A1 (0.62) | ALDH1A1TDP1CASP6ADAMTS4HCAR3 | |
| SCHEMBL2958562 | 0.83 | ALDH1A1 (0.92) | ALDH1A1TDP1ADAMTS4TSHRPOLB | |
| SCHEMBL44392 | 0.83 | ALDH1A1 (1.00) | ALDH1A1TDP1ADAMTS4TSHRMAPK1 | |
| SCHEMBL30196067 | 0.83 | ALDH1A1 (1.00) | ALDH1A1TDP1ADAMTS4TSHRMAPK1 | |
| Benzene SCHEMBL28038982 | 0.83 | ALDH1A1 (1.00) | ALDH1A1TDP1ADAMTS4TSHRMAPK1 | |
| SCHEMBL9557826 | 0.83 | CASP6 (0.66) | TDP1CASP6ERN1HCAR3TSHR | |
| SCHEMBL28669741 | 0.82 | ALDH1A1 (0.64) | ALDH1A1TDP1CASP6ERN1HCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240389450-A1 | LIGHT EMITTING ELEMENT, PRODUCTION METHOD FOR LIGHT EMITTING ELEMENT, DISPLAY DEVICE, AND PRODUCTION METHOD FOR DISPLAY DEVICE | Sharp Display Technology Corporation (JP) | 2024-11-21 | — | — | US | disclosed |
| US-20240376076-A1 | INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) | DANA-FARBER CANCER INSTITUTE, INC. | 2024-11-14 | — | — | US | disclosed |
| EP-4373816-A1 | INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) | Dana-Farber Cancer Institute, Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| CN-117981493-A | Light-emitting element, method for manufacturing light-emitting element, display device, and method for manufacturing display device | 夏普显示科技株式会社 | 2024-05-03 | — | — | CN | disclosed |
| WO-2023079616-A1 | LIGHT EMITTING ELEMENT, PRODUCTION METHOD FOR LIGHT EMITTING ELEMENT, DISPLAY DEVICE, AND PRODUCTION METHOD FOR DISPLAY DEVICE | シャープディスプレイテクノロジー株式会社 | 2023-05-11 | — | — | WO | disclosed |
| WO-2023003973-A1 | INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-01-26 | — | — | WO | disclosed |
| CN-103172612-A | Dibenzo iodonium salts and anticancer application thereof | UNIV SUN YAT SEN CANCER CT | 2013-06-26 | — | — | CN | disclosed |
| US-8008301-B2 | (2-(S)-Pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-(4'-trifluoromethyl-biphenyl-4-yl)-methanone; treatment of nervous system disorder, obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | ELI LILLY AND COMPANY (US) | 2011-08-30 | — | — | US | disclosed |
| US-7745424-B2 | Alkane diol derivatives as therapeutic agents for the treatment of bone conditions | The Univeristy Court of the University of Aberdeen (GB) | 2010-06-29 | — | — | US | disclosed |
| US-20100048580-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | BEAVERS LISA SELSAM | 2010-02-25 | — | — | US | disclosed |
| EP-1778658-A2 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | Siena Biotech S.p.A. (IT) | 2007-05-02 | — | — | EP | disclosed |
| EP-1735278-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2006-12-27 | — | — | EP | disclosed |
| EP-1441716-B1 | ALKANE DIOL DERIVATIVES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | UNIV ABERDEEN (GB) | 2006-05-31 | — | — | EP | disclosed |
| WO-2006008133-A2 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | SIENA BIOTECH S.P.A. (IT) | 2006-01-26 | — | — | WO | disclosed |
| WO-2005097740-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-10-20 | — | — | WO | disclosed |
| US-20040254151-A1 | Alkane diol derivatives as therapeutic agents for the treatment of bone conditions | UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN, THE (GB) | 2004-12-16 | — | — | US | disclosed |
| EP-1441716-A1 | ALKANE DIOL DERIVATIVES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | The University Court of The University of Aberdeen (GB) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003037321-A1 | ALKANE DIOL DERIVATIVES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2003-05-08 | — | — | WO | disclosed |
| US-5965763-A | Biphenyl compounds | HOECHST MARION ROUSSEL (FR) | 1999-10-12 | — | — | US | disclosed |
| US-5827887-A | 5-ALPHA REDUCTASE INHIBITORS | ROUSSEL UCLAF (FR) | 1998-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048580-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | HRH3, HRH4, HCRTR1 | ALDH1A1 2304/4885TDP1 3770/4885MYC 4735/4885 |
| US-20240376076-A1 | INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) | USP7, USP47, USP2 | ALDH1A1 2692/4885TDP1 890/4885MYC 2977/4885 |
| US-20040254151-A1 | Alkane diol derivatives as therapeutic agents for the treatment of bone conditions | SOST, ENPP2, MSR1 | ALDH1A1 605/4885TDP1 588/4885MYC 3102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.